Pharmafile Logo

Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers

August 5, 2024 |  

Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.

OCP white paper

It reveals:

  • The critical role of OCPs in treatment decisions and cost management
  • Opportunities for manufacturers to share pre-approval information
  • Key evidence needs for pathway inclusion
  • Optimal communication strategies with OCP stakeholders
  • Future trends in pathway comprehensiveness

Essential reading for oncology market access professionals looking to stay ahead in an evolving landscape and gain actionable insights on communicating your oncology product’s value and optimizing its pathway positioning.

>> VISIT THE WHITE PAPER DOWNLOAD PAGE TO VIEW THE ARTICLE

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

How does Genesis Research Group ‘Innovate differently’?

New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to ‘Innovate differently’ and transform the way they engage…

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive…

World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group

A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies…

Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences

This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market…

Genesis Research Group RWD / HTA / regulatory / ECA webinar on 15 Feb: reserve your place!

On 15 February 2024, Carole Longson and Allie Sosinsky of Genesis Research Group, a leading global provider of tech-enabled real-world evidence, market access, and HEOR solutions, will present a webinar…